Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X.
This study describes the changes in risk factors for coronary heart disease in obese persons with syndrome X after orlistat-assisted weight loss. Data were available for 1,700 patients who completed 52 weeks of weight loss; 128 were defined as having syndrome X by being in the quintile with the highest plasma triglyceride levels (>2.2 mM/L) and the lowest high-density lipoprotein cholesterol (HDL, <1.0 mM/L) concentrations. Initial characteristics of those with syndrome X were similar to the 119 subjects (non-syndrome X) in the lowest quintile of plasma triglyceride (<0.975 mM/L) and highest quintile of HDL cholesterol (>1.5 mM/L). Subjects were placed on a calorie-restricted diet, and randomized to receive orlistat or placebo. Initial values were higher in those with syndrome X for diastolic blood pressure (p = 0.03), plasma insulin (p = 0.0001), triglyceride (p = 0.0001) concentrations, and ratio of low-density lipoprotein cholesterol to HDL cholesterol (p = 0.0001), and were lower for HDL cholesterol (p = 0.001) concentrations. Weight loss was greater in both groups of orlistat-treated patients (p = 0.026); in those with syndrome X, it was associated with a significant reduction in plasma insulin (p = 0.019) and triglyceride (p = 0.0001) concentrations, an increase in HDL cholesterol concentration, and a decrease in low-density lipoprotein/HDL cholesterol ratio (p = 0.0001). There were no significant changes in plasma insulin, triglycerides, or HDL cholesterol concentration in the non-syndrome X group. In conclusion, weight loss attenuates coronary heart disease risk factors in obese persons with syndrome X, and the risk factor reduction is enhanced with administration of orlistat.
Reaven
G
G
Division of Cardiovascular Medicine, Stanford University School of Medicine, Stanford, California 94305, USA. greaven@shaman.com
Segal
K
K
Hauptman
J
J
Boldrin
M
M
Lucas
C
C
D000328:Adult; D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D008076:Cholesterol, HDL / Q000097:blood; D004038:Diet, Reducing; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007328:Insulin / Q000097:blood; D007783:Lactones / Q000627:therapeutic use*; D008049:Lipase / Q000037:antagonists & inhibitors*; D008297:Male; D017566:Microvascular Angina / Q000150:complications / Q000517:prevention & control*; D008875:Middle Aged; D009765:Obesity / Q000150:complications / Q000517:prevention & control*; D000077403:Orlistat; D012307:Risk Factors; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood; D015431:Weight Loss
D019440:Anti-Obesity Agents; D008076:Cholesterol, HDL; D007328:Insulin; D007783:Lactones; D014280:Triglycerides; D000077403:Orlistat; D008049:Lipase